This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Astex Pharmaceuticals Announces Presentation Of Updated Results Of SGI-110-01 Study In Patients With Intermediate Or High Risk Relapsed Or Refractory Myelodysplastic Syndromes At The European Hematology Association

DUBLIN, Calif., June 14, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that updated clinical results of its novel hypomethylating agent, SGI-110, were presented in a poster session at the 18th Congress of the European Hematology Association (EHA) being held June 13-16, 2013 in Stockholm, Sweden.

The update focused on details of the biological and clinical activity as well as safety in the group of intermediate or high risk relapsed or refractory myelodysplastic syndromes (r/r MDS) patients treated in the dose-escalation phase 1 part of the SGI-110-01 study. The study enrolled 15 intermediate or high risk MDS patients including chronic myelomonocytic leukemia who were heavily pretreated with a median number of prior regimens of 2 (range 2-6 prior regimens). All 15 patients had received prior azacitidine or decitabine, and 40% of them previously received both agents.

Of the 15 patients, six achieved a clinical response (4 patients with hematological improvement or HI, and 2 patients with marrow CR or mCR) for an overall response rate of 40% (95% CI of 16-68%).  The median duration of response was 92 days (range 28-126 days).  The two mCR patients received prior treatment with both azacitidine and decitabine, and they demonstrated pronounced DNA demethylation of  >10% as measured by the LINE-1 assay (19% and 38% demethylation of LINE-1). SGI-110 subcutaneous treatment was well tolerated.  The most common adverse events were injection site pain (mostly Grade 1), and myelosuppression.

"We are pleased with the updated results that continue to demonstrate promising clinical activity of SGI-110 in MDS patients who were heavily pre-treated. These data confirm the potent demethylation activity of this medicine," commented James S.J. Manuso, Ph.D., Astex Pharmaceuticals chief executive officer and chairman. "We are proceeding aggressively with the enrollment in the dose-expansion phase 2 part of the study of intermediate and high risk MDS patients who are either relapsed/refractory or treatment-naive to prior hypomethylating agents."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs